A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

[1]  D. Sargent,et al.  Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy , 2005 .

[2]  M. Seymour.  Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): A 2135-patient randomized trial in advanced colorectal cancer (ACRC) , 2005 .

[3]  I. Tannock,et al.  A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. de Gramont,et al.  Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer , 2003, American journal of clinical oncology.

[7]  C. Fuchs,et al.  Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Ducreux,et al.  Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Grothey.  Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) , 2002 .

[10]  R. Danesi,et al.  Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Khayat,et al.  Prospective Phase II Trial of Irinotecan, 5-Fluorouracil, and Leucovorin in Combination as Salvage Therapy for Advanced Colorectal Cancer , 2001 .

[12]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[13]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[14]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[16]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[17]  G. Peters,et al.  Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. , 1999, European journal of cancer.

[18]  M. Ychou,et al.  Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Lotz,et al.  CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.

[20]  J. Hainsworth,et al.  A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma , 1999, Cancer.

[21]  E. Van Cutsem,et al.  Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). , 1999, European journal of cancer.

[22]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[23]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[24]  C. Erlichman,et al.  Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity , 1998, Cancer Chemotherapy and Pharmacology.

[25]  S. Guichard,et al.  Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo , 1997 .

[26]  R. Goldberg,et al.  Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .